Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 18 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

39%

7 trials in Phase 3/4

Results Transparency

50%

6 of 12 completed trials have results

Key Signals

1 recruiting6 with results

Enrollment Performance

Analytics

Phase 3

7(43.8%)

Phase 2

5(31.3%)

Phase 1

4(25.0%)

16Total

Phase 3(7)

Phase 2(5)

Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials

NCT07003919Phase 3Recruiting

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

Role: lead

NCT05741476Phase 3Active Not Recruiting

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

Role: lead

NCT05424731Unknown

Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children

Role: lead

NCT02636699Phase 3Completed

Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy

Role: lead

NCT03859700Phase 3Completed

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

Role: lead

NCT03211247Phase 3Completed

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

Role: lead

NCT02223182Phase 1Completed

Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy

Role: lead

NCT04492683Phase 2Unknown

Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children

Role: lead

NCT01955109Phase 2Completed

Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children

Role: lead

NCT01675882Phase 2Completed

Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy

Role: lead

NCT04371627Unknown

Viaskin® Peanut (DBV712) Expanded Access Protocol

Role: lead

NCT02916446Phase 3Completed

Safety Study of Viaskin Peanut to Treat Peanut Allergy

Role: lead

NCT03013517Phase 3Unknown

Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children

Role: lead

NCT03035370Phase 1Completed

Viaskin Pertussis Vaccine Trial

Role: lead

NCT03352726Phase 1Completed

A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

Role: lead

NCT02579876Phase 2Completed

Milk Patch for Eosinophilic Esophagitis

Role: collaborator

NCT01197053Phase 2Completed

Epicutaneous Immunotherapy in Peanut Allergy in Children

Role: collaborator

NCT01170286Phase 1Completed

Safety of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy

Role: lead

All 18 trials loaded